Market Currents
Inovio Pharmaceuticals (INO +14.8%) pops after announcing Phase I clinical results indicating...
-
Wednesday, October 10, 2012, 3:46 PM ETInovio Pharmaceuticals (INO +14.8%) pops after announcing Phase I clinical results indicating that its DNA-based synthetic vaccine VGX-3100 is not only capable of boosting immune responses to antigens from high risk types of human papillomavirus infection, but also killing cells changed by the virus into precancerous dysplasias.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
